Lymphoid Malignancies Clinical Trials

27 clinical trials for Lymphoid Malignancies across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies — RECRUITING · PHASE1
• UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy — RECRUITING · PHASE1
• A PHASE 1, DOSE-ESCALATION/DOSE-EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF ORALLY ADMINISTERED CB-5083 IN SUBJECTS WITH LYMPHOID HEMATOLOGICAL MALIGNANCIES — RECRUITING · PHASE1
• A PHASE I/II STUDY OF PEMBROLIZUMAB (MK-3475) IN CHILDREN WITH ADVANCED MELANOMA OR A PD-L1 POSITIVE ADVANCED, RELAPSED OR REFRACTORY SOLID TUMOR OR LYMPHOMA (KEYNOTE-051) — RECRUITING · PHASE1
• Allogeneic iNKT Cell Therapy (agenT-797) After SCT — NOT_YET_RECRUITING · PHASE1
• Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies — COMPLETED · PHASE1
• RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies — COMPLETED · PHASE1
• A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy — COMPLETED · PHASE1
• Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies — TERMINATED · PHASE1
• ACY-1215 for Relapsed/Refractory Lymphoid Malignancies — TERMINATED · PHASE1
• Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT — OTHER · PHASE2
• AN OPEN-LABEL, PHASE 1/2 STUDY EVALUATING AVM0703 IN PATIENTS WITH LYMPHOID MALIGNANCIES (OPAL STUDY) — NOT_YET_RECRUITING · PHASE1
• Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies — COMPLETED · PHASE1
• A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies — COMPLETED · PHASE1
• Intra-Osseous Co-Transplant of UCB and hMSC — COMPLETED · PHASE1
• Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820 — TERMINATED · PHASE4
• Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation — COMPLETED · PHASE1
• A PHASE 2, OPEN-LABEL, MONOTHERAPY, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INCB054828 IN SUBJECTS WITH MYELOID/LYMPHOID NEOPLASMS WITH FGFR1 REARRANGEMENT — COMPLETED · PHASE2
• Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult Lymphoid Malignancies — COMPLETED · PHASE2
• Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System — TERMINATED · PHASE1
• A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies — COMPLETED · PHASE1
• A PHASE I STUDY EVALUATING SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ESCALATING DOSES OF AGS67E GIVEN AS MONOTHERAPY IN SUBJECTS WITH REFRACTORY OR RELAPSED LYMPHOID MALIGNANCIES — COMPLETED · PHASE1
• A PHASE 1B STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF GS 9820 MONOTHERAPY AND COMBINATION THERAPY IN SUBJECTS WITH LYMPHOID MALIGNANCIES — NOT_YET_RECRUITING · PHASE1
• A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies — TERMINATED · PHASE1
• RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies — COMPLETED · PHASE1
• Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies — COMPLETED · PHASE1
• Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders — TERMINATED · PHASE2

Refine this search